Gavin C. Hirst

1.5k citations

23 papers · 731 indexed · h-index 15

Co-authors: Larry E. Overman Theodore Johnson David J. Calderwood Andrew Burchat Biqin Li Robert F. Stachlewitz S Ratnofsky David W. Borhani
Topics: Immune Cell Function and Interaction (4 papers)Cytokine Signaling Pathways and Interactions (4 papers)Signaling Pathways in Disease (3 papers)
Cited by: Organic Chemistry Oncology Toxicology
Journals: Journal of the American Chemical Society Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: United States United Kingdom

In The Last Decade

Gavin C. Hirst

23 papers receiving 686 citations

Peers

Countries citing papers authored by Gavin C. Hirst

Since Specialization

Citations

This map shows the geographic impact of Gavin C. Hirst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gavin C. Hirst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gavin C. Hirst more than expected).

Fields of papers citing papers by Gavin C. Hirst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gavin C. Hirst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gavin C. Hirst. The network helps show where Gavin C. Hirst may publish in the future.

Co-authorship network of co-authors of Gavin C. Hirst

This figure shows the co-authorship network connecting the top 25 collaborators of Gavin C. Hirst. A scholar is included among the top collaborators of Gavin C. Hirst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gavin C. Hirst. Gavin C. Hirst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Determination of a Focused Mini Kinase Panel for Early Identification of Selective Kinase Inhibitors 2018 ·Journal of Chemical Information and Modeling ·Scott D. Bembenek,Gavin C. Hirst,Taraneh Mirzadegan	11
2	Fragment-based discovery of JAK-2 inhibitors 2008 ·Bioorganic & Medicinal Chemistry Letters ·Stephen Antonysamy,Gavin C. Hirst,(unknown),Paul A. Sprengeler,Frank Stappenbeck,Ruo W. Steensma,Mark R. Wilson,Melissa S. Wong	64
3	Synthesis and activity of N-cyanoguanidine-piperazine P2X7 antagonists 2008 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Diana L. Donnelly‐Roberts,Michael Friedman,Jonathan S. George,Gavin C. Hirst,(unknown),(unknown),Biqin Li,(unknown),(unknown),(unknown),Marian T. Namovic,Paul Rafferty,(unknown),Edit Tarcsa,(unknown),Kevin R. Woller	9
4	Discovery of thienopyridines as Src-family selective Lck inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),Andrew Burchat,David J. Calderwood,(unknown),Peter Hrnčiar,Gavin C. Hirst,Biqin Li,(unknown),(unknown),Bryant H. Yang	17
5	Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection 2005 ·Bioorganic & Medicinal Chemistry Letters ·Andrew Burchat,David W. Borhani,David J. Calderwood,Gavin C. Hirst,Biqin Li,Robert F. Stachlewitz	63
6	A-770041, a Novel and Selective Small-Molecule Inhibitor of Lck, Prevents Heart Allograft Rejection 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Robert F. Stachlewitz,(unknown),Brian R. Bettencourt,(unknown),Annette Schwartz,S Ratnofsky,David J. Calderwood,Wendy Waegell,Gavin C. Hirst	45
7	A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection 2004 ·Bioorganic & Medicinal Chemistry Letters ·David W. Borhani,David J. Calderwood,Michael Friedman,Gavin C. Hirst,Biqin Li,Adelaine Kwun-Wai Leung,(unknown),S Ratnofsky,Kurt Ritter,Wendy Waegell	30
8	Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases 2004 ·International Immunopharmacology ·Bradford L. McRae,(unknown),(unknown),(unknown),(unknown),Yong Jia,David H. Presky,Daniel E. Tracey,Gavin C. Hirst	9
9	Utilization of Microarrayed Compound Screening (μARCS) to Identify Inhibitors of p56lck Tyrosine Kinase 2004 ·SLAS DISCOVERY ·(unknown),Julie A. Wilkins,(unknown),James L. Kofron,Yong Jia,Gavin C. Hirst,David J. Burns,Usha Warrior	5
10	A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection 2002 ·Transplantation Proceedings ·Wendy Waegell,(unknown),(unknown),(unknown),(unknown),(unknown),Michael W. Leach,S Ratnofsky,A. Bèlanger,Gavin C. Hirst,Aldo A. Rossini,Michael Appel,John P. Mordes,Dale L. Greiner,Samir Banerjee	18
11	Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck — a selectivity insight 2002 ·Bioorganic & Medicinal Chemistry Letters ·Andrew Burchat,David J. Calderwood,Michael Friedman,Gavin C. Hirst,Biqin Li,Paul Rafferty,Kurt Ritter,(unknown)	48
12	Pyrazolo[3,4‐d]pyrimidines Containing an Extended 3‐Substituent as Potent Inhibitors of Lck — A Selectivity Insight. 2002 ·ChemInform ·Andrew Burchat,David J. Calderwood,Michael Friedman,Gavin C. Hirst,Biqin Li,Paul Rafferty,Kurt Ritter,(unknown)	1
13	Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection. 2001 ·PubMed ·Joanne Kamens,S Ratnofsky,Gavin C. Hirst	16
14	Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of lck II 2000 ·Bioorganic & Medicinal Chemistry Letters ·Andrew Burchat,David J. Calderwood,Gavin C. Hirst,(unknown),(unknown),(unknown),Paul Rafferty,(unknown)	40
15	Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists 1997 ·Journal of Medicinal Chemistry ·Brad R. Henke,Christopher Aquino,Larry S. Birkemo,Dallas K. Croom,R. W. Dougherty,Gregory N. Ervin,Mary K. Grizzle,Gavin C. Hirst,Michael K. James,Michael F. Johnson,Kennedy L. Queen,Ronald G. Sherrill,Elizabeth E. Sugg,Edward M. Suh,(unknown),Rayomand J. Unwalla,(unknown),Timothy M. Willson	63
16	Conversion of acyclic nonpeptide CCK antagonists into CCK agonists 1997 ·Bioorganic & Medicinal Chemistry Letters ·Gavin C. Hirst,Kennedy L. Queen,(unknown),Timothy M. Willson	3
17	Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity (II): Optimization of the C3 Amino Substituent 1996 ·Journal of Medicinal Chemistry ·Gavin C. Hirst,Christopher Aquino,(unknown),Dallas K. Croom,Milana Dezube,R. W. Dougherty,Gregory N. Ervin,Mary K. Grizzle,Brad R. Henke,Michael K. James,Michael F. Johnson,(unknown),Kennedy L. Queen,Ronald G. Sherrill,Jerzy Szewczyk,Timothy M. Willson,Elizabeth E. Sugg	31
18	Benzofuran based angiotensi II antagonists related to GR117289: Part II; amino acid amides 1993 ·Bioorganic & Medicinal Chemistry Letters ·David Middlemiss,Steve P. Watson,Barry C. Ross,Michael D. Dowle,D. I. C. SCOPES,John G. Montana,Gavin C. Hirst,(unknown),(unknown),Thomas Hubbard,(unknown),G.M. Drew,A. Hilditch,(unknown),Mark J. Robertson,(unknown),(unknown),Gary R. Manchee	3
19	First total synthesis of Lycopodium alkaloids of the magellanane group. Enantioselective total syntheses of (-)-magellanine and (+)-magellaninone 1993 ·Journal of the American Chemical Society ·Gavin C. Hirst,Theodore Johnson,Larry E. Overman	106
20	Regiochemical control of the Diels–Alder reactions with β-phenylsulphonylacrylate esters 1987 ·Journal of the Chemical Society Chemical Communications ·Antony D. Buss,Gavin C. Hirst,Philip J. Parsons	16

About Gavin C. Hirst

Gavin C. Hirst is a scholar working on Toxicology, Organic Chemistry and Physiology, having authored 23 papers that have together received 731 indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (4 papers), Cytokine Signaling Pathways and Interactions (4 papers) and Signaling Pathways in Disease (3 papers). The work is most often cited by research in Organic Chemistry (298 citations), Oncology (166 citations) and Toxicology (19 citations). Gavin C. Hirst has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Larry E. Overman, Theodore Johnson, David J. Calderwood, Andrew Burchat, Biqin Li, Robert F. Stachlewitz, S Ratnofsky, David W. Borhani, Paul Rafferty and Kennedy L. Queen. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact